MiMedx Group
MiMedx Group's revenue rose 20.0% to $419 million in fiscal 2025. Its operating margin was 15.3%, down from 16.9% a year earlier. The diluted share count rose 0.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What MiMedx Group does
MiMedx sells products that help heal chronic and hard-to-heal wounds, and it also serves burn care and surgery. Clinicians typically use them when a patient is slow to respond, or doesn't respond, to conventional treatment.
Historically its products were made from placental tissue, which is human birth tissue donated by mothers and processed into products that can treat many people. In 2024 it added animal-derived products, called xenografts. In 2025 and early 2026 it signed agreements with makers of other wound care products to widen what it offers. It says it gets tissue through a donor network of hospitals and clinician groups that it built over more than a decade.
Its revenue depends on insurers and health systems reimbursing the cost of its products. It competes with established tissue processors and medical device makers.
Its biggest risks, as it describes them
- Many of its products depend on tissue from human donors, so a supply disruption would hurt it.
- Its revenue depends on insurers and health systems paying for its products, and reimbursement rules can change.
- Competition from established tissue processors and device makers, and rapid technology change.
- It depends on its senior leaders, and changes in leadership can disrupt the business.
Income statement
From fiscal 2017 to 2025, earnings per share fell 6.8% a year and net income 3.5% a year, as new shares raised the share count by 29% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 87 | 66 | 82 | 104 | 166 |
| Debt incl. finance leases | 50 | 50 | 50 | 19 | 18 |
| Net debt (negative means net cash) | −37 | −16 | −32 | −85 | −148 |
| Net debt to EBITDA | — | — | −0.8x | −1.3x | −1.9x |
| Debt to equity | — | — | 0.3x | 0.1x | 0.1x |
| Interest coverage | −1.6x | −2.9x | 5.7x | 14.9x | 35.8x |
| Current ratio | 3.5x | 3.1x | 3.6x | 4.2x | 4.3x |
| Quick ratio | 3.2x | 2.8x | 3.1x | 3.7x | 3.9x |
Cash flow
Projections
Project MiMedx Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of MiMedx Group reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 5 of 9 | 7 of 9 |
| Rule of 40 | 27.7% | — | — |
| Altman Z'' | 4.02 | 6.87 | 8.06 |
| Accruals ratio | 15.3% | −9.5% | −8.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 7 of 9 | 5 of 9 | 7 of 9 |
Compare
Put MiMedx Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MiMedx Group | FY25 | 20.0% | 15.3% | — | 43.3% | −1.9x | 7 | |
| Accuray | FY26 | −12.3% | −6.6% | −3.2% | — | — | — | Compare |
| Artivion | FY25 | 13.6% | 7.7% | 0.2% | 3.9% | 2.7x | 7 | Compare |
| InMode | FY25 | −6.2% | 23.1% | 22.8% | — | — | — | Compare |
| Inogen | FY25 | 3.9% | −8.7% | −3.9% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 222 | 321 | 359 | 299 | 248 | 242 | 268 | 322 | 349 | 419 |
| Revenue growth | 18.4% | 44.9% | 11.8% | −16.7% | −17.1% | −2.5% | 10.7% | 20.0% | 8.5% | 20.0% |
| Gross profit | 191 | 286 | 323 | 256 | 209 | 202 | 220 | 267 | 289 | 346 |
| Research and development | 14 | 18 | 16 | 11 | 12 | 10 | 13 | 13 | 12 | 15 |
| Operating income | 1 | 46 | −4 | −21 | −45 | −7 | −15 | 37 | 59 | 64 |
| Net income | 0 | 65 | −30 | −26 | −49 | −10 | −30 | 58 | 42 | 49 |
| Diluted EPS (US$) | 0.00 | 0.56 | −0.28 | −0.24 | −0.77 | −0.15 | −0.33 | 0.37 | 0.28 | 0.32 |
| Diluted shares (millions) | 113 | 116 | 106 | 107 | 108 | 110 | 113 | 146 | 149 | 150 |
| Cash flow | ||||||||||
| Cash from operations | 24 | 63 | 36 | −39 | −30 | −2 | −18 | 27 | 66 | 74 |
| Capital expenditure | — | — | — | — | — | 3 | 2 | 2 | — | — |
| Free cash flow | — | — | — | — | — | −5 | −19 | 25 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 10 | 68 | 8 | 0 | 1 | 0 | 0 | 10 | 0 | 0 |
| Acquisitions | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 |
| Stock-based compensation | 18 | 21 | 15 | 12 | 15 | 14 | 11 | 17 | 17 | 16 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 30 | 28 | 45 | 69 | 96 | 87 | 66 | 82 | 104 | 166 |
| Debt incl. finance leases | — | — | 0 | 73 | 50 | 50 | 50 | 50 | 19 | 18 |
| Total assets | 117 | 121 | 123 | 167 | 202 | 188 | 171 | 239 | 264 | 343 |
| Total liabilities | 69 | 48 | 73 | 133 | 111 | 95 | 97 | 96 | 71 | 86 |
| Shareholders' equity | 48 | 74 | 50 | 34 | −0 | 0 | −18 | 143 | 193 | 256 |
| Margins and ratios | ||||||||||
| Gross margin | 86.0% | 89.0% | 89.9% | 85.6% | 84.2% | 83.6% | 82.0% | 83.0% | 82.8% | 82.6% |
| Operating margin | 0.4% | 14.4% | −1.1% | −7.1% | −18.3% | −2.9% | −5.5% | 11.6% | 16.9% | 15.3% |
| Net margin | 0.2% | 20.2% | −8.3% | −8.6% | −19.9% | −4.2% | −11.3% | 18.1% | 12.2% | 11.6% |
| Free cash flow margin | — | — | — | — | — | −2.1% | −7.2% | 7.7% | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −4.7% | 3.4% | 27.7% | — | — |
| Return on capital | — | — | — | −77.8% | — | — | — | 96.5% | 39.5% | 43.3% |
| Return on equity | 0.9% | 106.2% | −48.6% | −60.9% | −287.8% | — | — | 93.4% | 25.3% | 21.6% |
| Return on assets | 0.3% | 54.3% | −24.6% | −17.6% | −26.7% | −5.3% | −16.8% | 28.4% | 16.9% | 16.0% |
| Net debt to EBITDA | — | — | −15.1x | — | — | — | — | −0.8x | −1.3x | −1.9x |